AN2 Therapeutics, Inc. (ANTX)
US — Healthcare Sector
Automate Your Wheel Strategy on ANTX
With Tiblio's Option Bot, you can configure your own wheel strategy including ANTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
ANTX
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
AN2 Therapeutics (ANTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About AN2 Therapeutics, Inc. (ANTX)
- IPO Date 2022-03-25
- Website https://www.an2therapeutics.com
- Industry Biotechnology
- CEO Eric E. Easom
- Employees 22
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.